Kluin-Nelemans.

Hallek, S. Kremers, G. Lepeu, L. Sanhes, J.M. Zijlstra, R. Bouabdallah, P.J. Lugtenburg, M. Macro, M. Pfreundschuh, V. Di Raimondo, V. Ribrag, M. Uppenkamp, M. Klapper, W. Hiddemann, M. Unterhalt, and M.H. Dreyling: Treatment of Old Patients with Mantle-Cell Lymphoma Patients with mantle-cell lymphoma typically present with extensive disease and involvement of multiple lymph nodes along with the spleen, bone marrow, blood, and gastrointestinal tract.The composite of loss of life, rehospitalization for myocardial infarction, or stent thrombosis during the entire follow-up period happened in 448 and 490 sufferers in the two groupings, respectively . In a per-protocol analysis that included only individuals who received the randomly assigned therapy, the hazard ratio for death at 1 year was 0.95 and the hazard ratio for the composite of death, rehospitalization for myocardial infarction, or stent thrombosis was 0.94 . The results were consistent across all prespecified subgroups and several post hoc subgroups, including those based on hospital size and enrollment price, and subgroups connected with high thrombotic risk, such as for example patients who had a TIMI flow quality of 0 or 1, a thrombus grade of G5 or G4, a proximal lesion, or a brief delay from indicator onset to PCI and those who smoked .